Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed newly diagnosed glioblastoma multiforme or anaplastic astrocytoma
• * Residual tumor on postoperative MRI
• Bidimensionally measurable disease
• PATIENT CHARACTERISTICS:
• Age:
• Under 65
• Performance status:
• Karnofsky or Lansky 70-100% OR
• ECOG 0-2
• Life expectancy:
• Not specified
• Hematopoietic:
• Absolute neutrophil count at least 1,000/mm\^3
• Hemoglobin at least 8 g/dL (transfusion allowed)
• Platelet count greater than 100,000/mm\^3
• Hepatic:
• Bilirubin less than 1.5 times upper limit of normal (ULN)
• SGPT no greater than 3 times ULN
• Renal:
• Age 5 years and under: Creatinine less than 1.2 mg/dL
• Age over 5 to 10 years: Creatinine less than 1.5 mg/dL
• Age over 10 to 15 years: Creatinine less than 1.8 mg/dL
• Age over 15 years: Creatinine less than 2.4 mg/dL
• Cardiovascular:
• No myocardial infarction within the past 6 months
• Other:
• No other concurrent serious medical condition that would preclude study
• Able to tolerate oral medications
• No prior malignancy for which patient received prior chemotherapy or spinal irradiation
• No history of severe allergic reaction to platinum-containing compounds
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 72 hours since prior filgrastim (G-CSF)
• Chemotherapy:
• No prior chemotherapy
• No other concurrent chemotherapy
• Endocrine therapy:
• Concurrent steroids for tumor-related cerebral edema allowed
• No concurrent corticosteroids for solely antiemetic purposes
• Radiotherapy:
• No prior or concurrent radiotherapy
• Surgery:
• Recovered from prior surgery
• No concurrent surgery